Archive of WILEX Press Releases

Selected press releases of the former years can be found here.

 2007

 2006

 2005

 2004

08 October 2004

WILEX acquires option for US marketing rights to RENCAREX®*

20 September 2004

WILEX starts clinical trial with new anti-cancer compound WX-671

09 August 2004

Niels Ackermann appointed Chief Financial Officer and Member of the Executive Board of WILEX AG

15 June 2004

WILEX starts patient enrollment in RENCAREX®* pivotal Phase III trial in Renal Cell Carcinoma

25 May 2004

WILEX and Fox Chase Cancer Center begin clinical trial in the U.S. with novel compound WX-UK1 targeting tumor cell invasion and metastasis

10 May 2004

WILEX receives IND approval from FDA for Phase III trial with RENCAREX®* in Renal Cell Carcinoma

06 May 2004

Niels Ackermann to Head Finance Department at WILEX AG

26 April 2004

WILEX and Esteve sign co-development and marketing agreement for RENCAREX®* in Southern Europe

01 March 2004

WILEX’s antibody RENCAREX®* shows positive long term survival in follow-up of Phase II trial in Renal Cell Carcinoma patients

14 January 2004

WILEX starts clinical Phase I trial with anti-cancer compound WX-UK1 in head and neck cancer patients

 2003

 2002 and earlier